Philadelphia chromosome-positive leukemia in adults is a blood cancer driven by a swap between chromosomes 9 and 22 that creates the BCR-ABL1 fusion gene. It is found in almost all cases of chronic myeloid leukemia (CML) and in a substantial minority of adult acute lymphoblastic leukemia (ALL). Targeted pills called tyrosine kinase inhibitors have changed the outlook dramatically, turning CML into a long-term, manageable condition for most patients and improving results in Ph-positive ALL.
This article explains where the Philadelphia chromosome comes from, how it shows up, how it is tested, and how treatment works. It sits within the wider field of adult hematology, and I have written it for patients and families as well as students.
What the Philadelphia Chromosome Is
The Philadelphia chromosome is a shortened chromosome 22 formed by a reciprocal translocation, written as t(9;22). Part of the ABL1 gene on chromosome 9 joins the BCR gene on chromosome 22. The resulting fusion gene makes an abnormal enzyme, a tyrosine kinase, that is permanently switched on.
This overactive enzyme tells blood-forming cells to keep dividing and to resist normal cell death. The change happens in a single cell in the marrow during a person’s lifetime. It is acquired, not inherited, so it is not passed to children.
Which Leukemias Carry It
| Feature | Chronic myeloid leukemia (CML) | Ph-positive acute lymphoblastic leukemia (Ph+ ALL) |
|---|---|---|
| How often Ph is present | Nearly all cases | A minority of adult ALL, more common with increasing age |
| Speed of illness | Usually slow in the chronic phase | Acute; develops over days to weeks |
| Typical blood count | Very high white cell count with maturing cells | Blasts (immature cells), often low red cells and platelets |
| Main fusion protein | Usually p210 | Often p190, sometimes p210 |
| Core treatment | TKI tablets, often for years | TKI combined with chemotherapy or immunotherapy, with transplant for selected patients |
Risk Factors
For most adults there is no identifiable cause. Known associations include:
- Age: CML is most often diagnosed in middle and older age, and Ph+ ALL becomes a larger share of ALL as age rises.
- Sex: CML is slightly more common in men.
- High-dose ionizing radiation: seen historically in atomic bomb survivors and after some radiation treatments.
Lifestyle and diet have not been shown to cause the translocation, and family members do not need screening.
Symptoms and How It Presents
Many adults with CML have no symptoms, and the diagnosis is made when a routine blood test shows a high white cell count. When symptoms occur, they tend to include:
- Fatigue and reduced exercise tolerance from anemia.
- Fullness or discomfort under the left ribs, or feeling full quickly, from an enlarged spleen.
- Night sweats, weight loss, and low-grade fevers.
Ph+ ALL behaves differently. Patients usually become unwell quickly with tiredness, breathlessness, infections, easy bruising or bleeding, and bone pain. This needs urgent assessment.
Phases of CML
CML is traditionally described as chronic phase, where most patients are diagnosed, and an advanced or blast phase, where the disease behaves like acute leukemia. Effective treatment in chronic phase is the main way to prevent progression.
Diagnosis and Testing
Diagnosis combines hematologic and genetic tests. Our guide to testing for leukemia in adults covers the wider workup.
- Complete blood count and blood film: shows a raised white count and the types of cells present.
- Bone marrow examination: bone marrow aspiration and biopsy determine the phase of CML or confirm ALL, drawing on the normal structure described in the composition and function of bone marrow.
- Karyotype: looks at all chromosomes and detects t(9;22) plus any extra changes.
- FISH: fluorescent probes find the BCR-ABL1 fusion even when cells do not divide well.
- Quantitative PCR: measures the amount of BCR-ABL1 transcript and becomes the main tool for monitoring.
Treatment Options
Tyrosine kinase inhibitors (TKIs) block the abnormal BCR-ABL1 enzyme directly. Their arrival is one of the great success stories in cancer medicine.
Chronic Myeloid Leukemia
- First-line TKIs: imatinib, dasatinib, nilotinib, and bosutinib. The choice depends on risk features, other health conditions, and side-effect profiles.
- Later-line options: ponatinib and asciminib are used after resistance or intolerance, including for the T315I mutation, which blocks most earlier TKIs.
- Stem cell transplant: now reserved for advanced disease or failure of several TKIs.
- Treatment-free remission: some patients with deep, sustained responses can stop their TKI under close molecular monitoring.
Ph-Positive ALL
Adults with Ph+ ALL receive a TKI alongside chemotherapy or steroids, and increasingly with immunotherapy such as blinatumomab. An allogeneic stem cell transplant is considered in first remission for many fit patients, especially if minimal residual disease remains detectable.
Common TKI Side Effects
Side effects vary by drug but can include fatigue, nausea, muscle cramps, rash, fluid retention, and low blood counts. Some TKIs carry specific risks such as fluid around the lungs, blood vessel problems, or effects on the heart, liver, or pancreas, so regular monitoring is part of treatment.
Monitoring Response
In CML, response is tracked with BCR-ABL1 PCR, usually every three months at first. Results are reported on an International Scale, and the goal is a steady fall over the first year. A result at or below 0.1% is called a major molecular response. A rising level prompts a check on adherence and testing for resistance mutations.
Key Takeaways
- Philadelphia chromosome-positive leukemia in adults results from t(9;22) and the BCR-ABL1 fusion gene.
- It is found in nearly all CML and in a minority of adult ALL.
- The change is acquired during life, not inherited.
- TKIs have made CML a long-term condition for most patients and improved Ph+ ALL outcomes.
- Regular PCR monitoring and taking every dose are essential to long-term control.
Frequently Asked Questions
Is Philadelphia chromosome-positive leukemia hereditary?
No. The translocation develops in a single marrow cell during a person’s lifetime. It is not present in eggs or sperm, so it is not passed to children.
Can Philadelphia-positive CML be cured?
Most people with chronic-phase CML who respond well to a TKI can expect a near-normal life expectancy. Some reach a deep enough response to stop treatment safely under monitoring, and stem cell transplant can be curative in selected cases.
How long do people take TKI tablets?
Many take a TKI for years. Stopping is only considered after a long, deep molecular response and must be done with frequent PCR checks, because some patients need to restart.
Is Ph-positive ALL worse than Ph-negative ALL?
Ph+ ALL was historically considered high risk. Adding TKIs and newer immunotherapies has markedly improved results, and the outlook now depends heavily on age, overall fitness, and how deeply the disease responds.
